Statistical explanations for a community-based study of once-weekly epoetin alfa therapy in patients receiving chemotherapy [2]

Journal of Clinical Oncology

Volumn 20, Issue 11, 2002, Pages 2757-2758

  Gabrilove, Janice L ^a   Sarokhan, Brenda ^a   Cremieux, Pierre ^a  

^a MA

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER PATIENT; COMMUNITY CARE; HEMOGLOBIN DETERMINATION; HUMAN; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT OUTCOME;

EID: 0036605803     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.20.11.2757     Document Type: Letter

References (4)

1. Clinical evaluation of once-weekly and three-times-weekly dosings of alfa in chemotherapy patients: Problems of study design and interpretation
2. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvement in hemoglobin and quality of life are similar to three-times-weekly dosing
3. Quality-of-life in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study
4. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systematic sclerosis trial